falsefalse

Intracranial Efficacy of Next-Generation ALK-Targeted Therapies

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    1. All: Please discuss the efficacy of ALK inhibitors in brain metastases.
      1. REMARK study (Xiong A, et al. 2024. WCLC. OA09.03)
      2. CROWN trial (Solomon BJ, et al. Lancet Respir Med. 2023)
      3. ALTA-3 (Yang JC, et al. J Thorac Oncol. 2023)
      4. ALTA-1L/brigatinib (Camidge DR, et al. J Clin Oncol. 2021)
    2. Others

    Related Content:

    Leveraging ctDNA Platforms in High-Risk Patients: Current Applications and Future Potential
    Translating Metastatic Insights to Early-Stage Management: Current Practices and Future Direction
    EGFR Therapy Evolution: Resistance Mechanisms, Combination Strategies, and Advanced Testing
    x